Unknown

Dataset Information

Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.


ABSTRACT:

Background

Treatment of refractory ascites in liver cirrhosis is challenging. Transjugular intrahepatic portosystemic shunt and alfapump® have been proposed for the management, but few data comparing both exist.

Aims

The aim of this study was to evaluate the characteristics and outcomes of patients treated with transjugular intrahepatic portosystemic shunt and alfapump® for refractory ascites at our centre.

Methods

All consecutive patients were retrospectively reviewed for baseline characteristics, efficacy of treatment, complications and survival.

Results

In total, 19 patients with transjugular intrahepatic portosystemic shunt and 40 patients with alfapump® were included. Patients with transjugular intrahepatic portosystemic shunt had better liver function and

SUBMITTER: Will V 

PROVIDER: S-EPMC7707873 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature